January 31, 2012—Synedgen Inc. announces the appointment of Joyce Vu as Senior Regulatory Analyst. Ms. Vu brings 15 years experience in regulatory affairs to Synedgen. She is well skilled in domestic and international regulatory processes, regulatory compliance issues including protocols, SOPs (Standard Operating Procedures), New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Investigational New [...]
SoCalBio Women, Work & Wisdom (W3) Quarterly Business Mixer Features Dr. Shenda Baker, Synedgen, Inc. President and COO as its Keynote Speaker
January 23, 2012 —Synedgen President, Shenda Baker PhD, has been invited to deliver a keynote presentation at the Southern California Biomedical Council Women, Work & Wisdom (W3) Quarterly Business Mixer on February 16, 2012. Dr. Baker will discuss Synedgen’s pipeline antimicrobial products and the challenges facing small pharmaceutical companies in today’s regulatory climate. W3 is a [...]
Synedgen Founder & CEO Appointed UC Professor of Surgery
October 1, 2011 — Synedgen Founder & CEO William P. Wiesmann MD has been appointed Volunteer Professor of Surgery, Division of Research, at the University of Cincinnati. In addition to his academic appointment, Dr. Wiesmann was also appointed to the Advisory Board of the UC Institute for Military Medicine, which was created in 2009 to [...]
Synedgen Research Results Demonstrate New Therapy for Cystic Fibrosis Patients
Chitosan Derivative Dissolves Biofilms, Reduces Mucus Viscosity and Enhances the Antibacterial Power of Tobramycin September 14, 2011 — Synedgen, Inc. announces new research results demonstrating that its proprietary chitosan derivative, SYN01, effectively dissolves biofilms, reduces mucus viscosity, and maintains broad antibiotic activity against Pseudomonas aeruginosa, a common cause of lung infection associated with cystic fibrosis. [...]
Biotech Firm Synedgen Announces Research Results Demonstrating Significant Antimicrobial Activity against Food-borne pathogens by its lead Chitosan Derivative
Chitosan Derivatives Reduce E. coli and coliform concentrations in models of food contamination July 13, 2011 — New research conducted jointly between Synedgen, Inc., and the School of Environment, Natural Resources and Geography, at Bangor University, Bangor, UK demonstrates that a novel biocompatible and bactericidal chitosan derivative developed by Synedgen offers a rapid and safe [...]
Biotech Firm Synedgen Announces Research Results of New Antibacterial Wound Treatment
Wound Rinse Removes Bacteria and Biofilms Without Damaging Tissue May 20, 2011 — Synedgen will report recent data from its studies of a new wound rinse at a poster session May 23 at ASM 2011, the annual meeting of the American Society for Microbiology in New Orleans. The poster, Novel Antibacterial Chitosan Derivatives with Residual [...]
Synedgen Receives $1.96 million from the NIH to Accelerate the Development of a Promising New Treatment for Oral Mucositis
Treatment is being developed to reduce oral infection and pain associated with cancer treatments March 21, 2011 (Honolulu, HI & Claremont CA) – Biotech firm Synedgen announces the award of a competitive Phase II SBIR grant by the National Institutes of Health (NIH) to accelerate the development of Synedgen’s proprietary oral disease treatments. Under this [...]
Synedgen and University of New South Wales Partner to Improve Bone Regeneration
September 30, 2010 — Synedgen and the University of New South Wales will investigate therapies to improve bone growth and wound healing as part of a new project sponsored by the Australian Research Council’s Linkage Project Grants program. [...]
Synedgen Announces Successful Results of NIH-Funded Research into Treatment of Multi-drug Resistant Bacterial Infections in Wounds
September 16, 2010 — Synedgen announced today the completion of a highly successful research study funded by the the National Institutes of Health (NIH) that shows the ability of their wound decontamination rinse to kill highly drug-resistant bacteria. [...]
Shenda Baker Named President of Synedgen, Inc.
Sept. 9, 2010 — Shenda Baker, Ph.D., has been named president and chief operating officer at Synedgen, Inc., a bio-pharmaceutical company committed to developing novel therapies and products to save live in hospitals, on the battlefield, in our food supply and in the home. [...]